The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat topic 11/16: Running on Empty—Advocacy and Burnout
- #LCSM Chat Topic 11/2: What Was Your Favorite #LCSM Chat, and Why?
- #LCSM Chat Topic 10/19: World Conference on Lung Cancer (#WCLC2017) Wrap-Up
- #LCSM Chat Topic 10/5: Lung Cancer Advocacy: How we can help ourselves
- #LCSM Chat Topic 9/21: Patient-Clinician Communication in Cancer Care: Conflicting Ideals vs. Reality?
#LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment patient advocates PCORI Screening self-advocacy shared decision making trials World Cancer Day